Free Trial

Bright Minds Biosciences (DRUG) Insider Trading & Ownership

Bright Minds Biosciences logo
$38.65 -0.46 (-1.18%)
(As of 12/20/2024 05:31 PM ET)

Bright Minds Biosciences (NASDAQ:DRUG) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
42.66%
Number Of
Insiders Buying
(Last 12 Months)
1
Amount Of
Insider Buying
(Last 12 Months)
$2.06 M
Number Of
Insiders Selling
(Last 12 Months)
0
Get DRUG Insider Trade Alerts

Want to know when executives and insiders are buying or selling Bright Minds Biosciences stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

DRUG Insider Buying and Selling by Quarter

Bright Minds Biosciences Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/15/2024Cormorant Asset Management, LpMajor ShareholderBuy372,591$5.53$2,060,428.23  
(Data available from 1/1/2013 forward)

DRUG Insider Trading Activity - Frequently Asked Questions

The list of insiders at Bright Minds Biosciences includes Cormorant Asset Management, Lp. Learn more on insiders at DRUG.

42.66% of Bright Minds Biosciences stock is owned by insiders. Learn more on DRUG's insider holdings.

The following insider purchased DRUG shares in the last 24 months: Cormorant Asset Management, Lp ($2,060,428.23).

Insiders have purchased a total of 372,591 DRUG shares in the last 24 months for a total of $2,060,428.23 bought.

Bright Minds Biosciences Key Executives

  • Mr. Ian McDonald (Age 35)
    Co-Founder, CEO, President & Director
  • Mr. Ryan E. S. K. Cheung B.Com. (Age 46)
    CA, CPA, Chief Financial Officer
    Compensation: $89.23k
  • Dr. Jan Torleif Pedersen M.Sc. (Age 59)
    Ph.D., Chief Science Officer & Director
    Compensation: $181.09k
  • Dr. Mark A. Smith M.D. (Age 69)
    Ph.D., Chief Medical Officer
    Compensation: $243.54k
  • Mr. Alex Vasilkevich
    COO & VP of Corporate Development
  • Dr. Emer Leahy M.B.A. (Age 57)
    Ph.D., Consultant


This page (NASDAQ:DRUG) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners